ICAM1 and lymphoid leukemia: For the six prioritised drug targets, several additional beneficial effects of these targets (in addition to their effects on COVID-19 severity) were observed, which included inhibition of FCRL3 level on reducing rheumatoid arthritis, lymphoid leukaemia, hypothyroidism and hyperthyroidism; increased OAS1 level on reducing Alzheimer's disease risk; and inhibition of ICAM1 level on reducing risk of neo-extraversion, hypertension and skin cancer and reducing body mass index and diastolic blood pressure level (Table S12A).